JCM
ALDX icon

JS Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

JS Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-19,200
Closed -$132K – 140
2020
Q4 		$132K Buy
+19,200
New +$135K 0.01% 133

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

JS Capital Management's ALDX Position: Q1 2021 in Review

JS Capital Management sold out of Aldeyra Therapeutics (ALDX) in Q1 2021, closing a stake of 19,200 shares — an estimated $132K sold.

JS Capital Management first reported a position in ALDX in Q4 2020 and held it in 1 quarter. The position peaked at $132K in Q4 2020. 108 funds tracked by Wall St. Rank hold ALDX as of Q1 2021.

  • JS Capital Management reported no remaining Aldeyra Therapeutics position as of Q1 2021 after selling out during the quarter.
  • JS Capital Management sold 19,200 Aldeyra Therapeutics shares in Q1 2021, an estimated $132K.
  • JS Capital Management first reported a position in Aldeyra Therapeutics in Q4 2020 and held it in 1 quarter.
  • JS Capital Management's Aldeyra Therapeutics position peaked at $132K in Q4 2020.
  • 108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2021.

Based on JS Capital Management's 13F filing for Q1 2021, filed 17 May 2021.